Ever Supreme Bio Technology Co., Ltd (TPEX: 6712)
Taiwan
· Delayed Price · Currency is TWD 176.50
-1.00 (-0.56%)
Sep 10, 2024, 1:30 PM CST
Ever Supreme Bio Technology Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2016 |
|---|---|---|---|---|---|---|---|
Period Ending | Jun '24 Jun 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2016 |
| Revenue | 823.57 | 758.39 | 627.51 | 438.84 | 70.6 | 10.82 | Upgrade
|
| Revenue Growth (YoY) | 31.15% | 20.86% | 42.99% | 521.61% | 552.53% | - | Upgrade
|
| Cost of Revenue | 246.71 | 273.64 | 212.96 | 193.36 | 88.54 | 8.55 | Upgrade
|
| Gross Profit | 576.86 | 484.75 | 414.56 | 245.48 | -17.95 | 2.27 | Upgrade
|
| Selling, General & Admin | 48.56 | 47.91 | 40.07 | 45.14 | 29.91 | 43.25 | Upgrade
|
| Research & Development | 103.13 | 99.11 | 90.69 | 84.14 | 109.25 | 94.51 | Upgrade
|
| Operating Expenses | 174.59 | 147.02 | 130.76 | 129.28 | 139.16 | 137.75 | Upgrade
|
| Operating Income | 402.27 | 337.73 | 283.8 | 116.2 | -157.11 | -135.49 | Upgrade
|
| Interest Expense | -0.16 | -0.2 | -0.51 | -0.62 | -0.78 | -0.58 | Upgrade
|
| Interest & Investment Income | 9.4 | 14.18 | 9.88 | 6 | 3.65 | 6.52 | Upgrade
|
| Currency Exchange Gain (Loss) | 9.81 | 21.76 | -30.72 | - | - | - | Upgrade
|
| Other Non Operating Income (Expenses) | 10.94 | 7.52 | 7.35 | 4.27 | 2.58 | 0.01 | Upgrade
|
| EBT Excluding Unusual Items | 432.25 | 380.99 | 269.79 | 125.85 | -151.66 | -129.54 | Upgrade
|
| Gain (Loss) on Sale of Investments | 170.27 | 241.86 | -5.7 | 261.05 | 14.31 | 9.92 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | -0 | 11.33 | -0.05 | -0.01 | Upgrade
|
| Asset Writedown | - | - | - | -1.94 | - | - | Upgrade
|
| Other Unusual Items | 0.07 | 0.17 | 0.01 | 0.52 | - | - | Upgrade
|
| Pretax Income | 602.6 | 623.01 | 264.1 | 396.82 | -137.4 | -119.62 | Upgrade
|
| Income Tax Expense | 91.89 | 83.62 | 63.39 | 27.22 | -30.57 | -25.4 | Upgrade
|
| Net Income | 510.71 | 539.4 | 200.71 | 369.6 | -106.83 | -94.22 | Upgrade
|
| Net Income to Common | 510.71 | 539.4 | 200.71 | 369.6 | -106.83 | -94.22 | Upgrade
|
| Net Income Growth | 52.54% | 168.74% | -45.69% | - | - | - | Upgrade
|
| Shares Outstanding (Basic) | 81 | 82 | 82 | 82 | 75 | 75 | Upgrade
|
| Shares Outstanding (Diluted) | 81 | 82 | 83 | 83 | 75 | 75 | Upgrade
|
| Shares Change (YoY) | -1.60% | -0.84% | 0.15% | 11.01% | 0.09% | 6.37% | Upgrade
|
| EPS (Basic) | 6.30 | 6.58 | 2.44 | 4.51 | -1.43 | -1.26 | Upgrade
|
| EPS (Diluted) | 6.27 | 6.56 | 2.42 | 4.46 | -1.44 | -1.26 | Upgrade
|
| EPS Growth | 54.92% | 171.42% | -45.83% | - | - | - | Upgrade
|
| Free Cash Flow | 417.89 | 415.92 | 316.02 | 133.7 | -197.3 | -126.78 | Upgrade
|
| Free Cash Flow Per Share | 5.13 | 5.06 | 3.81 | 1.61 | -2.65 | -1.70 | Upgrade
|
| Dividend Per Share | 5.455 | 5.455 | 1.653 | 3.758 | - | - | Upgrade
|
| Dividend Growth | 229.90% | 229.90% | -56.00% | - | - | - | Upgrade
|
| Gross Margin | 70.04% | 63.92% | 66.06% | 55.94% | -25.42% | 20.94% | Upgrade
|
| Operating Margin | 48.84% | 44.53% | 45.23% | 26.48% | -222.54% | -1252.31% | Upgrade
|
| Profit Margin | 62.01% | 71.12% | 31.99% | 84.22% | -151.32% | -870.87% | Upgrade
|
| Free Cash Flow Margin | 50.74% | 54.84% | 50.36% | 30.47% | -279.48% | -1171.86% | Upgrade
|
| EBITDA | 420.73 | 357.69 | 307.28 | 141.47 | -135.61 | -123.41 | Upgrade
|
| EBITDA Margin | 51.09% | 47.16% | 48.97% | 32.24% | -192.09% | - | Upgrade
|
| D&A For EBITDA | 18.47 | 19.96 | 23.48 | 25.27 | 21.5 | 12.08 | Upgrade
|
| EBIT | 402.27 | 337.73 | 283.8 | 116.2 | -157.11 | -135.49 | Upgrade
|
| EBIT Margin | 48.84% | 44.53% | 45.23% | 26.48% | -222.54% | - | Upgrade
|
| Effective Tax Rate | 15.25% | 13.42% | 24.00% | 6.86% | - | - | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.